Pathology Revenue Cycle Management: The 7 Stages, and Where Practices Actually Lose Money

By Godavari Doke Sr. Content Writer Reviewed By Samuel Stone Pathology Revenue Cycle Management: The 7 Stages, and Where Practices Actually Lose Money Table of

Godavari Doke
September 16, 2026

TL;DR

Pathology revenue cycle management runs on seven stages: intake, eligibility check, coding, claim scrubbing, AR and denial management, payment posting, and analytics. Pathology billing tracks each specimen, not each visit. That is why PC/TC splits and molecular coding trip up practices that copy their billing playbook from general medicine. Most revenue does not leak across all seven stages. It leaks in two or three: coding errors on molecular and IHC claims, poor denial follow-up, and AR that drifts past 40 days unnoticed. Two numbers tell you the truth fast: a net collection rate above 95%, and AR days under 35.

A biopsy report leaves the pathologist’s desk clean. A Gleason score. Negative margins. Everything the doctor needs to plan treatment. Six weeks later, the payment shows up $340 short. Nobody in the billing office can say why, not at first glance. Was it the modifier? The specimen count? A missed medical necessity code?

That gap, between a perfect pathology report and a claim that pays in full, is where most practices lose money. Not in one big, dramatic spot. In small, repeat mistakes spread across seven stages most practices have never actually mapped.

This post breaks pathology RCM into its seven working parts. It names the two or three stages where revenue actually leaks. And it gives you two numbers to check against your own books this week.

What Is Pathology RCM, and How Is It Different From Lab RCM?

Pathology revenue cycle management turns a specimen into a paid claim. It covers intake, coding, billing, and collections; everything that has to happen right along the way. Here is the distinction that matters: pathology billing tracks the specimen, not the visit. A physician’s office bills once per visit. A pathology practice bills for every specimen, every stain, and every read attached to it, and each one carries its own billing rules.

That single difference is why general revenue cycle advice, written for physician offices, falls short for pathologists. A few things make this specialty different:

PC/TC split billing: When a hospital owns the equipment and a pathologist reads the slide, the bill splits in two. The technical work bills under modifier -TC. The professional read bills under modifier -26. Get the split wrong, and the claim gets flagged for duplicate billing or denied outright.
Tier 1 and Tier 2 molecular coding: Genetic tests do not fit one simple code, the way a basic blood panel does. Codes in the 81000 to 81479 range must match the exact gene, method, and clinical reason for the test. Payers check this documentation more closely every year.
IHC is billed per antibody, per block: Codes 88342 through 88346 depend on a log of every antibody used on the specimen. Miss the count, and the claim underbills the practice or gets kicked back for a mismatch.
Frozen sections and LCD rules: Frozen section notes have to match the payer’s Local Coverage Determination, the rule that defines when a test counts as medically necessary. If they do not line up, the claim fails on a technicality, even when the diagnosis itself is correct.

None of this makes pathology RCM harder in some abstract way. It runs on different logic than physician billing, and a revenue cycle built for office visits will miss exactly the spots where pathology claims fail.

“Standard TAT” Has a Billing Equivalent

Lab teams already know this pattern from turnaround time. A practice can have a “standard” fee schedule and a policy that says every claim gets coded right. What actually happens on a Tuesday, with 200 specimens backed up, is a different number entirely. Revenue cycle management exists to close that gap. It works the same way TAT monitoring closes the gap between a written policy and the bench.

7 Core Stages of Pathology RCM

Every pathology claim moves through seven stages before it turns into cash: intake, eligibility check, coding, claim scrubbing, AR and denial management, payment posting, and analytics. Skip or rush any one stage, and the damage does not stay put. It shows up three steps later, as a denial nobody can trace back to its source.

Stage	What Happens	Highest Risk
1. Intake	Capture demographics, insurance ID, and specimen data	Wrong or incomplete patient and payer information
2. Eligibility Verification	Confirm coverage and flag pre-authorization needs	High-complexity tests billed without prior auth
3. Coding	Assign CPT and ICD-10 codes, including PC/TC splits	Molecular and IHC coding errors, the single riskiest stage
4. Claim Scrubbing	Run claims through clearinghouse checks before submission	Formatting and modifier errors that trigger automatic denials
5. AR & Denial Management	Work denials by root cause, not blind resubmission	Claims aging past 90 days with no follow-up plan
6. Payment Reconciliation	Post payments, manage lockbox data, resolve credit balances	Unposted or misapplied payments hiding true AR
7. Analytics	Track KPIs like net collection rate and AR days	Flying blind until a monthly report surfaces the problem

1. Intake

Intake captures the patient's name, insurance ID, and specimen details before a single test runs. Get a policy number wrong, or a birth date wrong, and every step after inherits that error. This works the same way sample accessioning does. It is just the billing side of the same record

2. Eligibility Verification

This step checks coverage. It flags pre-authorization needs before a costly molecular test reaches the bench. Skipping it does not save time. It just moves the discovery of a coverage problem to after the specimen is already used, a far more expensive place to find out.

3. Coding

Coding assigns the right codes: surgical, cytology, or molecular. This is where PC/TC splits and molecular coding do the most damage. These are the codes general billing staff see least often, so they get them wrong most often too. Practices that route molecular and IHC claims to a dedicated coder, instead of spreading them across the whole team, see far fewer denials.

4. Claim Scrubbing

Claim scrubbing runs every claim through clearinghouse software before it goes out. It catches formatting errors, missing modifiers, and bad code combinations, ideally within 24 hours of coding. A claim that clears scrubbing is not guaranteed to pay. A claim that skips it is almost guaranteed to bounce.

5. AR & Denial Management

This is where practices either get ahead of a problem or fall behind it for good. Root-cause analysis means tracing a denial back to the exact coding or documentation gap that caused it. That is what separates a practice that fixes its process from one that just resubmits the same mistake with a new date stamp.

6. Payment Reconciliation

Reconciliation posts payments from insurers and patients. It manages lockbox data and clears credit balances. It sounds like simple bookkeeping. It is actually where a lot of “phantom AR” hides: money that arrived weeks ago but never got matched to the right claim. It still shows up as unpaid on every report the practice runs.

7. Analytics

Analytics tracks the numbers that tell you if the other six stages are working: net collection rate, AR days, and denial rate by payer and test type. A practice that checks these once a quarter is flying the same way a lab flies when it only reviews TAT at month-end. By the time the report lands, six weeks of damage is already done.

Where Most Practices Actually Lose Revenue

Most pathology practices do not lose revenue evenly across all seven stages. The leak concentrates in two or three spots: coding errors on molecular and IHC claims, poor denial follow-up, and AR that ages past 90 days before anyone acts. Pathology billing is not harder than general medical billing in some general sense. The highest-risk stages just happen to be the ones general billing staff touch least.

XiFin processes claims data for labs nationwide. Its numbers show routine pathology claims run close to a 10% denial rate. Molecular testing runs meaningfully higher, because of medical necessity documentation and prior authorization rules. That gap alone explains why a molecular-heavy practice needs a tighter front end than one running mostly routine surgical pathology.

Two benchmarks are worth checking every month, both pulled from MGMA and HFMA data on physician group billing:

Metric	Industry Average	High-Performing Practices
Net Collection Rate	90 to 95%	Above 95 to 96%
Days in AR	40 days or higher	Below 30 to 35 days
Initial Denial Rate	Up to 8%	Below 3%

A 90% net collection rate is not a crisis. But it is real money left on the table every month, quietly enough that it rarely gets noticed until someone runs the numbers. Take a practice billing $3 million a year. The gap between a 90% and a 96% net collection rate works out to roughly $180,000 a year. That is not a rounding error on a P&L. That is a coding hire, a denial management contract, or a system upgrade, paid for by revenue the practice already earned.

Billing staff knows this pattern by heart:

A stack of remittances flagged CO-252 for missing documentation.
A molecular claim bounced back because the payer says the gene panel was not medically necessary.
The same denial reason, typed into the same spreadsheet, for the third week running.

None of that is a payer problem. It is a process gap. And process gaps are fixable, in a way that “the payers are just difficult” never is.

How Pathologists and Pathology Practices Use RCM Software Day to Day

Strip away the dashboards, and what a practice manager wants from RCM software is simple: a live view of every claim, at every stage, without waiting on IT to run a report. That is the real difference between true end-to-end RCM software and a billing system that just processes claims and hopes for the best.

Picture a practice manager on a Monday morning. She wants to see which claims are stuck in eligibility checks before they hit the bench. She wants to see which denials from last week still need review. She wants to know if last month’s net collection rate held above 95%. That is not a feature list. It is a daily habit, and it only works if coding, scrubbing, and AR tracking live in one connected system, not three tools that do not talk to each other.

CrelioHealth’s billing workflows connect coding, scrubbing, and denial tracking to the same system a pathology practice already uses for specimen and case management. A coding error surfaces before the claim goes out, not three weeks after it comes back denied. It is one example of what integrated pathology RCM looks like in daily use, not a sales pitch, just a practical answer to what a practice manager needs to see each morning.

Frequently Asked Questions

What is pathology revenue cycle management?

Pathology revenue cycle management turns a specimen into a paid claim. It covers intake, eligibility checks, coding, claim scrubbing, AR and denial management, payment posting, and analytics. It tracks the specimen, not the visit, which sets it apart from general physician billing.

How is pathology RCM different from RCM for a general clinical lab?

Pathology RCM carries unique complexity: PC/TC split billing, Tier 1 and Tier 2 molecular coding, and per-antibody IHC billing rules. A general clinical lab’s fee schedule does not have to handle any of these.

What causes the most claim denials in pathology billing?

Coding errors on molecular and IHC claims cause most pathology denials. Missing or wrong PC/TC modifiers and LCD medical necessity mismatches are close behind, according to billing data from XiFin and CAP’s operational scorecards.

What is a good AR days benchmark for a pathology practice?

MGMA and HFMA data put the industry average around 40 days in AR. High-performing practices keep that number under 30 to 35 days. Anything past 50 days usually means slow claim submission, weak denial follow-up, or both

What software supports end-to-end RCM for pathology practices?

Good pathology RCM software handles coding review, claim scrubbing, and denial tracking in one connected system tied to case management, not as separate tools. CrelioHealth’s billing platform is one example built around that model.

The Bottom Line

Pathology RCM has seven stages. The honest news: most practices are not broken across all of them. Revenue loss concentrates in two or three spots: coding on molecular and IHC claims, denial management that resubmits instead of investigating, and AR that ages past the point anyone is watching.

Run the self-check this week. Pull your net collection rate. Pull your AR days. If either number misses the benchmark, you already know which stage to start with. And it is rarely the one that gets blamed first.

Revenue does not usually vanish all at once. It leaks, claim by claim, in the same two or three spots, until someone finally checks. For the full picture of pathology billing inside lab revenue cycle management, start with the Lab Revenue Cycle Management Guide, or book time with CrelioHealth to walk your own denial data against these benchmarks.

Pathology Revenue Cycle Management: The 7 Stages, and Where Practices Actually Lose Money

Table of Contents